{{Rsnum
|rsid=20455
|Gene=KIF6
|Chromosome=6
|position=39357302
|Orientation=minus
|ReferenceAllele=T
|MissenseAllele=C
|GMAF=0.4904
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=KIF6
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 11.5 | 51.3 | 37.2
| HCB | 23.5 | 47.8 | 28.7
| JPT | 25.7 | 45.1 | 29.2
| YRI | 79.0 | 19.6 | 1.4
| ASW | 62.5 | 32.1 | 5.4
| CHB | 23.5 | 47.8 | 28.7
| CHD | 20.2 | 43.1 | 36.7
| GIH | 22.8 | 39.6 | 37.6
| LWK | 64.2 | 31.2 | 4.6
| MEX | 7.0 | 45.6 | 47.4
| MKK | 35.6 | 43.6 | 20.8
| TSI | 7.9 | 54.5 | 37.6
| HapMapRevision=28
}}
[[rs20455]], often called Arg719 or 719Arg, is a reasonably well studied SNP in the [[KIF6]] gene. The risk allele (encoding the arginine at position 719) is [[rs20455]](C).

An extensive 2010 meta-analysis, including over 17,000 patients, suggests this variant does not significantly influence coronary artery disease risk.{{PMID|20933357|OA=1
}}

This SNP is one of the 5 used by [[Celera]]'s genetic risk score (GRS) for coronary [[heart disease]] (CHD). 

*[[rs20455]], in the [[KIF6]] gene
*[[rs3900940]], in the [[MYH15]] gene
*[[rs7439293]], in the [[PALLD]] gene
*[[rs2298566]], in the [[SNX19]] gene
*[[rs1010]], in the [[VAMP8]] gene

For each of the five variants, the GRS was increased by 1 if the subject was homozygous for the risk variant, unchanged if heterozygous, and decreased by 1 if the individual did not carry the variant. Therefore, individuals carrying all 10 possible risk variants (two copies of each of the five SNPs) were assigned a GRS of 5 and those carrying no risk variants a GRS of -5. A high GRS was defined as 3 or higher. Approximately 4% of the white cohort in ARIC was classified as high risk, and the hazard ratio for CHD after adjustment for traditional risk factors was a significant 1.57 (CI: 1.21-2.04; p<0.001). The results did not reproduce for African American participants.{{PMID|18073581}}

{{PMID|18222354}} Carriers of the 719Arg allele of KIF6 have 34% higher risk of [[myocardial infarction]] and 24% higher risk of coronary [[heart disease]] compared with noncarriers among 25,283 women.

{{PMID|18222355}} Carriers of 719Arg receive significantly greater benefit from intensive statin therapy than do noncarriers. The benefit from intensive (compared with moderate) statin therapy was significantly greater in the 59% of the 1,778 patients who were carriers (hazard ratio 0.59, CI: 0.45 -0.77) than in those who were noncarriers (HR 0.94, CI: 0.70-1.27; p=0.018 for interaction between 719Arg carrier status and treatment). The absolute risk reduction was 10.0% in carriers versus 0.8% in noncarriers.

{{PMID|18222353}} Untreated carriers of the [[rs20455]] risk allele had odds ratios for MI or stroke of 1.50 and 1.55 (CI: 1.05-2.15 or 1.14-2.09) in two large clinical trials. Among treated carriers, the absolute risk reduction by [[pravastatin]] therapy was 4.9% and 5.5% (CI: 1.81-7.9% or 3.5-7.5%). Therefore, in both trials carriers of a [[rs20455]](C) SNP had an increased risk of coronary events, and statin treatment (in this case, [[pravastatin]]) reduced that risk more for such carriers than for noncarriers.

{{PMID|20215968}} Elderly carriers of a [[rs20455]](C) (719Arg) allele with prior vascular disease received significant benefit from [[pravastatin]]; however, no benefit was observed in noncarriers with prior disease or in those without prior disease (carriers or noncarriers).

{{PMID|20403483}} Across all ethnic groups studied, [[pravastatin]] therapy significantly and substantially reduced both fatal coronary events and nonfatal myocardial infarctions only for carriers of the 719Arg allele (and not for noncarriers).

{{PharmGKB
|RSID=rs20455
|Name_s=KIF6:Trp719Arg
|Gene_s=KIF6
|Feature=
|Evidence=PubMed ID:18073581; PubMed ID:18222353; PubMed ID:18222354; PubMed ID:18222355
|Annotation=This variant is associated with an increased risk of myocardial infarction and coronary heart diseases.Pravastatin treatment substantially reduced that risk.
|Drugs=pravastatin
|Drug Classes=
|Diseases=Myocardial Infarction
|Curation Level=Curated
|PharmGKB Accession ID=PA161795944
}}

{{PMID Auto
|PMID=19752551
|Title=Polymorphisms associated with both noncardioembolic stroke and coronary heart disease: vienna stroke registry
|OA=1
}}

{{PMID Auto
|PMID=20886236
|Title=Genetic variants in the KIF6 region and coronary event reduction from statin therapy
|OA=1
}}

{{PMID Auto
|PMID=21435211
|Title=Survival bias and drug interaction can attenuate cross-sectional case-control comparisons of genes with health outcomes. An example of the kinesin-like protein 6 (KIF6) Trp719Arg polymorphism versus coronary heart disease
|OA=1
}}

{{PMID Auto
|PMID=22135385
|Title=The 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the TNT and IDEAL Prospective Studies
}}

{{PMID Auto
|PMID=22192511
|Title=KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly
}}

{{PMID Auto
|PMID=18799872
|Title=Single nucleotide polymorphisms associated with coronary heart disease predict incident ischemic stroke in the atherosclerosis risk in communities study.
|OA=1
}}

{{PMID Auto
|PMID=21458191
|Title=No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
}}

{{PMID Auto
|PMID=21810021
|Title=Investigation of KIF6 Trp719Arg in a case-control study of coronary artery disease in Western Indians.
}}

{{GET Evidence
|gene=KIF6
|aa_change=Trp719Arg
|aa_change_short=W719R
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs20455
|overall_frequency_n=5457
|overall_frequency_d=10758
|overall_frequency=0.50725
|n_genomes=38
|n_genomes_annotated=0
|n_haplomes=57
|n_articles=0
|n_articles_annotated=0
|in_pharmgkb=Y
|pph2_score=0.01
|nblosum100=7
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23001387
|Title=Association of KIF6 variant with lipid level and angiographic coronary artery disease events risk in the Han Chinese population.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}